Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

This study has been completed.
MacuSight, Inc.
Information provided by (Responsible Party):
Santen Inc. Identifier:
First received: April 4, 2008
Last updated: January 8, 2013
Last verified: July 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2012
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)